ArticleDisease markers2022
LC-MS-Based Lipidomic Analysis of Serum Samples from Patients with Type 2 Diabetes Mellitus (T2DM).
Article in Disease markers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
- Hepatocyte-Specific ApoJ Knockout Improves Metabolic Profiles in the Liver of Diabetic Mice.Metabolites · 2025Article
- Lipidomics Profiling of Metformin-Induced Changes in Obesity and Type 2 Diabetes Mellitus: Insights and Biomarker Potential.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Chewing the fat: How lipidomics is changing our understanding of human health and disease in 2022.Analytical science advances · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWith the development of social economy, type 2 diabetes mellitus (T2DM) is becoming a severe health problem globally.
methodsTo systematically understand the lipid metabolism in T2DM, we applied untargeted lipidomics to the serum of T2DM patients and control group using ultrahigh-performance liquid chromatography (UHPLC) coupled with high-resolution mass spectrometry (MS).
resultsOver two thousand molecular features were detected by our approach, of which 222 lipid species in positive ion mode and 145 species in negative were reliably identified based on precise molecular weights and MS/MS patterns. Multivariate analysis was adopted to differentiate T2DM patients and the control group using principal component analysis (PCA) and orthogonal partial least squares discrimination analysis (OPLS-DA). The dysregulated lipid species were found and their significance in pathophysiology was discussed. Correlation analysis of selected lipids and important clinical variables was performed and addressed.
conclusionsThis study unveils several new lipids and pathways considerably involved in T2DM and provides novel insights into understanding the pathogenesis underlying T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.